Discovering Some Novel 7-Chloroquinolines Carrying a Biologically Active Benzenesulfonamide Moiety as a New Class of Anticancer Agents
Loading...
Date
2013
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Chemical and Pharmaceutical Bulletin
Series Info
Chem. Pharm. Bull.;61(1) 50–58
Doi
Scientific Journal Rankings
Abstract
Based on the reported anticancer activity of quinolines, a new series of 7-chloroquinoline derivatives
bearing the biologically active benzenesulfonamide moiety 2–17 and 19–25 were synthesized starting
with 4,7-dichloroquinolne 1. Compound 17 was the most active compound with IC50 value 64.41, 75.05 and
30.71 μm compared with Doxorubicin as reference drug with IC50 values 82.53, 88.32 and 73.72 μm on breast
cancer cells, skin cancer cells and neuroblastoma, respectively. All the synthesized compounds were evaluated
for their in vitro anticancer activity on breast cancer cells, skin cancer cells and neuroblastoma cells.
Most of the synthesized compounds showed moderate activity. In order to suggest the mechanism of action
for their cytotoxic activity, molecular docking for all synthesized compounds was done on the active site of
phosphoinositide kinase (PI3K) and good results were obtained.
Description
MSA Google Scholar
Keywords
qunioline, sulfonamide, anticancer activity
Citation
1) Gopal M., Shenoy S., Doddamani L. S., J. Photochem. Photobiol. B, 72, 69–78 (2003). 2) Kim Y. H., Shin K. J., Lee T. G., Kim E., Lee M. S., Ryu S. H., Suh P. G., Biochem. Pharmacol., 69, 1333–1341 (2005). 3) Zhao Y. L., Chen Y. L., Chang F. S., Tzeng C. C., Eur. J. Med. Chem., 40, 792–797 (2005). 4) Wall M. E., Wani M. C., Cook C. E., Palmer K. H., McPhail A. T., Sims G. A., J. Am. Chem. Soc., 88, 3888–3890 (1966). 5) Ma Z. Z., Hano Y., Nomura T., Chen Y. J., Heterocycles, 46, 541–546 (1997). 6) Kobayash J., Cheng J., Nakamura H., Ohizumi Y., Hirata Y., Sasaki T., Ohta T., Nozoe S., Tetrahedron Lett., 29, 1177–1180 (1988). 7) Utsugi T., Aoyagi K., Asao T., Okazaki S., Aoyagi Y., Sano M., Wierzba K., Yamada Y., Jpn. J. Cancer Res., 88, 992–1002 (1997). 8) Jonckers T. H., van Miert S., Cimanga K., Bailly C., Colson P., De Pauw-Gillet M. C., van den Heuvel H., Claeys M., Lemière F., Esmans E. L., Rozenski J., Quirijnen L., Maes L., Dommisse R., Lemière G. L., Vlietinck A., Pieters L., J. Med. Chem., 45, 3497–3508 (2002). 9) Peczyńska-Czoch W., Pognan F., Kaczmarek L., Boratyński J., J. Med. Chem., 37, 3503–3510 (1994). 10) Drews J., Science, 287, 1960–1964 (2000). 11) Supuran C. T., Scozzafava A., Curr. Med. Chem. Immunol. Endocr. Metab. Agents, 1, 61–97 (2001). 12) Maren T. H., Annu. Rev. Pharmacol. Toxicol., 16, 309–327 (1976). 13) Boyd A. E. 3rd, Diabetes, 37, 847–850 (1988). 14) Thornber C. W., Chem. Soc. Rev., 8, 563–580 (1979). 15) Casini A., Scozzafava A., Mastrolorenzo A., Supuran L. T., Curr. Cancer Drug Targets, 2, 55–75 (2002). 16) Supuran C. T., Nat. Rev. Drug Discov., 7, 168–181 (2008). 17) Supuran C. T., Scozzafava A., Bioorg. Med. Chem., 15, 4336–4350 (2007). 18) Supuran C. T., Scozzafava A., Casini A., Med. Res. Rev., 23, 146– 189 (2003). 19) Knight S. D., Schmidt S. J., Smithkline beecham corporation, US Patent: US 8138347 (2008). 20) Ghorab M. M., Ragab F. A., Noaman E., Heiba H. I., El-Hossary E. M., Arzneimittelforschung, 57, 795–803 (2007). 21) Ghorab M. M., Ragab F. A., Noaman E., Heiba H. I., El-Hossary E. M., Arzneimittelforschung, 58, 35–41 (2008). 22) Hogle M. B., Shelar A. R., Kachare D. S., Salunkhe V. K., J. Indian Chem. Soc., 64, 314–316 (1987). 23) Zhong B., Al-Awar R. S., Shih C., Grimes J. H. Jr., Vieth M., Hamdouchi C., Tetrahedron Lett., 47, 2161–2164 (2006). 24) Weinstein I. B., Begemann M., Zhou P., Han E. K., Sgambato A., Doki Y., Arber N., Ciaparrone M., Yamamoto H., Clin. Cancer Res., 3, 2696–2702 (1997). 25) Weinstein I. B., Joe A. K., Nat. Clin. Pract. Oncol., 3, 448–457 (2006). 26) Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S. H., Zhang J., Signoretti S., Loda M., Roberts T. M., Zhao J. J., Nature, 454, 776–779 (2008). 27) Wee S., Wiederschain D., Maira S. M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y. M., Lengauer C., Proc. Natl. Acad. Sci. U.S.A., 105, 13057–13062 (2008). 28) Crabbe T., Welham M. J., Ward S. G., Trends Biochem. Sci., 32, 450–456 (2007). 29) Kim D., Kim S., Koh H., Yoon S. O., Chung A. S., Cho K. S., Chung J., FASEB J., 15, 1953–1962 (2001). 30) Boller D., Schramm A., Doepfner K. T., Shalaby T., von Bueren A. O., Eggert A., Grotzer M. A., Arcaro A., Clin. Cancer Res., 14, 1172–1181 (2008). 31) Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R., J. Natl. Cancer Inst., 82, 1107–1112 (1990)